Phase III Study of KX-826 With Adult Male Patients With AGA

Summary

This is a phase III, multi-center, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of KX-826 for topical use in Chinese adult male patients with androgenetic alopecia (AGA).

Timeline

Start

2021-12-29

Primary completion

2024-05-31

Completion

2024-05-31

Outcome

Met primary endpoint

release “KX-826 酊 1.0% 治疗脱发的关键性临床试验III期阶段已获得顶线数据。数据显示，该III期阶段达到主要研究终点” kintor.com.cn ↗

release “KX-826酊1.0%治疗脱发的关键性临床试验II期阶段已获得顶线数据。数据显示，该II期阶段达到主要研究终点” kintor.com.cn ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KX-826	Unknown	5 %	Topical

Indications